NCT06526104View on ClinicalTrials.gov

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

October 1, 2027

Study Completion Date

December 1, 2027

Conditions
Hepatocellular CarcinomaCirrhosis, Liver
Interventions
DRUG

Tremelimumab

Priming dose of tremelimumab 300 mg IV once (Cycle 1, Day 1 only)

DRUG

Durvalumab

Durvalumab 1500 mg IV on Day 1 of each 4-week cycle.

Trial Locations (1)

78229

RECRUITING

UT Health San Antonio, San Antonio

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER